Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...
The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...
Medical Device Network on MSN
FDA approves Abbott’s Volt PFA system for atrial fibrillation
The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for ...
April 17 (Reuters) - Abbott Laboratories (ABT.N), opens new tab beat Wall Street estimates for quarterly profit on Wednesday on robust sales of its medical devices, but the company's stock fell 3% in ...
July 20 (Reuters) - Abbott Laboratories (ABT.N), opens new tab on Thursday beat quarterly profit expectations as a rebound in surgical procedure volumes drove demand for medical devices despite high ...
Zacks.com on MSN
Abbott Gains From Lingo CGM's Expansion on Android Platform
Abbott Laboratories ABT recently announced that Lingo, its first over-the-counter biowearable continuous glucose monitor ...
Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...
Abbott (ABT) announced the U.S. FDA has approved the company’s Volt PFA System to treat patients battling atrial fibrillation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback